Management of Residual Tumor in Testicular Cancer

2019 ◽  
pp. 701-705
Author(s):  
David Pfister ◽  
Axel Heidenreich
Keyword(s):  
Testicular Cancer ◽  
Residual Tumor

1001: Retroperitoneal Residual Tumor (RTR) Resection for Testicular Cancer - Template Instead of Full Bilateral Resection

2007 ◽  
Vol 177 (4S) ◽  
pp. 331-331 ◽  
Author(s):  
Ralf Witthuhn ◽  
Patrick De Geeter ◽  
Peter Albers
Keyword(s):  
Testicular Cancer ◽  
Residual Tumor

Management of Residual Tumor in Testicular Cancer

2018 ◽  
pp. 1-5
Author(s):  
D. Pfister ◽  
A. Heidenreich
Keyword(s):  
Testicular Cancer ◽  
Residual Tumor

Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage III and bulky stage II nonseminomatous testicular cancer

Cancer ◽  
1985 ◽  
Vol 56 (2) ◽  
pp. 249-255 ◽  
Author(s):  
Giorgio Pizzocaro ◽  
Roberto Salvioni ◽  
Massimo Pasi ◽  
Fulvio Zanoni ◽  
Angelo Milani ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Combination Chemotherapy ◽  
Residual Tumor ◽  
Stage Ii ◽  
Stage Iii

Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?

1992 ◽  
Vol 10 (4) ◽  
pp. 569-573 ◽  
Author(s):  
S D Fosså ◽  
H Qvist ◽  
A E Stenwig ◽  
H H Lien ◽  
S Ous ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Tumor Markers ◽  
Primary Tumor ◽  
Residual Disease ◽  
Mature Teratoma ◽  
Residual Tumor ◽  
Retroperitoneal Lymph Node Dissection ◽  
Retroperitoneal Mass ◽  
Residual Masses ◽  
Minimal Residual

PURPOSE At least one third of the patients with metastatic testicular cancer are rendered tumor-free by cisplatin-based chemotherapy. One may question, therefore, the routine use of postchemotherapy retroperitoneal lymph node dissection (RLND), especially if the residual masses are less than 20 mm in diameter. To define the role of such surgery, we analyzed the postchemotherapy histology in testicular cancer patients with minimal residual disease. PATIENTS AND METHODS Seventy-eight patients with advanced nonseminomatous testicular cancer underwent RLND after three to four cycles of cisplatin- or carboplatin-based chemotherapy. In all patients, the largest diameter of the residual retroperitoneal mass was less than 20 mm. RESULTS Complete fibrosis/necrosis was found in 51 patients, mature teratoma in 22, and vital malignant germ cell tumor in five. In two of the latter five patients, alphafetoprotein (AFP) had increased immediately before RLND. In the 76 patients with normal pre-RLND tumor markers, the presence of undifferentiated malignant teratoma (MTU) in the primary tumor and normal prechemotherapy tumor markers were independent parameters predicting complete fibrosis/necrosis, which was demonstrated in all 15 patients with these two pretreatment parameters. CONCLUSIONS Postchemotherapy RLND can be omitted in patients with MTU in the primary tumor who have normal AFP/human chorionic gonadotropin (AFP/HCG) before chemotherapy and whose residual retroperitoneal mass is less than 20 mm in diameter. If the pre-RLND tumor markers are normal, RLND should be performed in all other patients with small residual masses, even in the presence of a normal computed tomography (CT) and particularly if regular follow-up of the patients is not guaranteed.

Predictive factors for the histologicnature of residual tumor mass after chemotherapy in patients with advanced testicular cancer

Urology ◽  
1994 ◽  
Vol 44 (3) ◽  
pp. 392-398 ◽  
Author(s):  
Hideyasu Matsuyama ◽  
Shigeru Hayashida ◽  
Norio Yamamoto ◽  
Yoriaki Kamiryo ◽  
Jisaburou Sakatoku ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Predictive Factors ◽  
Residual Tumor ◽  
Tumor Mass ◽  
Advanced Testicular Cancer ◽  
Residual Tumor Mass

Surgical resection of residual tumor masses after chemotherapy in testicular cancer

2012 ◽  
Vol 84 (2) ◽  
pp. 84-91
Author(s):  
D. P. Korkolis ◽  
Ch. Aggeli ◽  
I. Passas ◽  
E. Gontikakis
Keyword(s):  
Testicular Cancer ◽  
Surgical Resection ◽  
Residual Tumor

Retroperitoneal surgery in patients with nonseminomatous testicular cancer and minimal residual tumor

1992 ◽  
Vol 50 (4) ◽  
pp. 220-223 ◽  
Author(s):  
Hanne Qvist ◽  
Sophie Dorothea Fosså ◽  
Sigurd Ous ◽  
Hans H. Lien ◽  
Anna E. Stenwig ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Residual Tumor ◽  
Minimal Residual ◽  
Minimal Residual Tumor
Sign in / Sign up

Export Citation Format

Share Document